<?xml version="1.0" ?><!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st June 2018//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_180601.dtd"><PubmedArticleSet><PubmedArticle>    <MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM">        <PMID Version="1">30460281</PMID>        <DateRevised>            <Year>2018</Year>            <Month>11</Month>            <Day>21</Day>        </DateRevised>        <Article PubModel="Print-Electronic">            <Journal>                <ISSN IssnType="Electronic">2150-5551</ISSN>                <JournalIssue CitedMedium="Internet">                    <Volume>8</Volume>                    <Issue>3</Issue>                    <PubDate>                        <Year>2016</Year>                    </PubDate>                </JournalIssue>                <Title>Nano-micro letters</Title>                <ISOAbbreviation>Nanomicro Lett</ISOAbbreviation>            </Journal>            <ArticleTitle>Microfluidics: Rapid Diagnosis for Breast Cancer.</ArticleTitle>            <Pagination>                <MedlinePgn>204-220</MedlinePgn>            </Pagination>            <ELocationID EIdType="doi" ValidYN="Y">10.1007/s40820-015-0079-8</ELocationID>            <Abstract>                <AbstractText>Breast cancer affected 1.7 million people worldwide in 2012 and accounts for approximately 23.3Â % of all cancers diagnosed in women. The disease is characterized by a genetic mutation, either inherited or resulting from environmental factors, that causes uncontrollable cellular growth of breast tissue or adjacent tissues. Current means of diagnosing this disease depend on the individual analyzing the results from bulky, highly technical, and expensive equipment that is not globally accessible. As a result, patients can go undiagnosed due to a lack of available equipment or be over-diagnosed due to human error. This review attempts to highlight current means of diagnosing breast cancer and critically analyze their effectiveness and usefulness in terms of patient survival. An alternative means based on microfluidics biomarker detection is then presented. This method can be considered as a primary screening tool for diagnosing breast cancer based on its robustness, high throughput, low energy requirements, and accessibility to the general public.</AbstractText>            </Abstract>            <AuthorList CompleteYN="Y">                <Author ValidYN="Y">                    <LastName>Panesar</LastName>                    <ForeName>Satvinder</ForeName>                    <Initials>S</Initials>                    <AffiliationInfo>                        <Affiliation>BioNano Laboratory, School of Engineering, University of Guelph, Guelph, ON N1G 2W1 Canada.</Affiliation>                        <Identifier Source="GRID">grid.34429.38</Identifier>                        <Identifier Source="ISNI">0000000419368198</Identifier>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Neethirajan</LastName>                    <ForeName>Suresh</ForeName>                    <Initials>S</Initials>                    <AffiliationInfo>                        <Affiliation>BioNano Laboratory, School of Engineering, University of Guelph, Guelph, ON N1G 2W1 Canada.</Affiliation>                        <Identifier Source="GRID">grid.34429.38</Identifier>                        <Identifier Source="ISNI">0000000419368198</Identifier>                    </AffiliationInfo>                </Author>            </AuthorList>            <Language>eng</Language>            <PublicationTypeList>                <PublicationType UI="D016428">Journal Article</PublicationType>                <PublicationType UI="D016454">Review</PublicationType>            </PublicationTypeList>            <ArticleDate DateType="Electronic">                <Year>2016</Year>                <Month>01</Month>                <Day>08</Day>            </ArticleDate>        </Article>        <MedlineJournalInfo>            <Country>Germany</Country>            <MedlineTA>Nanomicro Lett</MedlineTA>            <NlmUniqueID>101727940</NlmUniqueID>            <ISSNLinking>2150-5551</ISSNLinking>        </MedlineJournalInfo>        <KeywordList Owner="NOTNLM">            <Keyword MajorTopicYN="N">Biomarkers</Keyword>            <Keyword MajorTopicYN="N">Breast cancer</Keyword>            <Keyword MajorTopicYN="N">Diagnostic technology</Keyword>            <Keyword MajorTopicYN="N">MiRNA</Keyword>            <Keyword MajorTopicYN="N">Mircofluidics</Keyword>        </KeywordList>    </MedlineCitation>    <PubmedData>        <History>            <PubMedPubDate PubStatus="received">                <Year>2015</Year>                <Month>09</Month>                <Day>27</Day>            </PubMedPubDate>            <PubMedPubDate PubStatus="accepted">                <Year>2015</Year>                <Month>12</Month>                <Day>04</Day>            </PubMedPubDate>            <PubMedPubDate PubStatus="entrez">                <Year>2018</Year>                <Month>11</Month>                <Day>22</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="pubmed">                <Year>2016</Year>                <Month>1</Month>                <Day>1</Day>                <Hour>0</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="medline">                <Year>2016</Year>                <Month>1</Month>                <Day>1</Day>                <Hour>0</Hour>                <Minute>1</Minute>            </PubMedPubDate>        </History>        <PublicationStatus>ppublish</PublicationStatus>        <ArticleIdList>            <ArticleId IdType="pubmed">30460281</ArticleId>            <ArticleId IdType="doi">10.1007/s40820-015-0079-8</ArticleId>            <ArticleId IdType="pii">79</ArticleId>            <ArticleId IdType="pmc">PMC6223681</ArticleId>        </ArticleIdList>        <?pmcsd?>    </PubmedData></PubmedArticle></PubmedArticleSet>